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Recent advance of sequencing technology has revealed genetic alterations in colorectal
cancer (CRC). The biological function of recurrently mutated genes has been intensively
investigated through mouse genetic models and CRC cell lines. Although these experi-
mental models may not fully reﬂect biological traits of human intestinal epithelium, they
provided insights into the understanding of intestinal stem cell self-renewal, leading to the
development of novel human intestinal organoid culture system. Intestinal organoid culture
enabled to expand normal or tumor epithelial cells in vitro retaining their stem cell self-
renewal and multiple differentiation. Gene manipulation of these cultured cells may provide
an attractive tool for investigating genetic events involved in colorectal carcinogenesis.
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INTRODUCTION
Despite recent advances in therapeutics, colorectal cancer (CRC)
is a major health issue; more than a million people develop CRC,
causingmore than 700 thousand deaths worldwide yearly (Lozano
et al., 2012). Surgically non-resectable tumors or metastatic dis-
ease ultimately acquires resistance to therapy, leading to death
(Cunningham et al., 2010). The notion that a limited num-
ber of cells within a cancer are exclusively capable of initiating
and maintaining the tumor, i.e., the cancer stem cell (CSC)
hypothesis, has recently been gaining favor, and CRC is no
exception. CSCs are referred to as being resistant to therapy,
responsible for tumor metastasis and recurrence, and poten-
tial targets of new therapeutic strategies. Investigators have
attempted to identify or isolate colorectal CSCs; however, direct
evidence of colorectal CSCs has been lacking to date (Clevers,
2011).
Recently, crypt base columnar cells (CBC cells) lying at the
bottom of intestinal crypts were shown to give rise to all lin-
eages of intestinal epithelial cells by genetic tracing of the Lgr5
gene (Barker et al., 2007). Genetic transformation of these Lgr5+
intestinal stem cells (ISCs) has shown their potential as tumor-
initiating cells (Barker et al., 2009). A method of maintaining and
expanding ISCs ex vivo has also been established (Sato et al., 2009).
This dramatic progress has provided new insight into ISC biology
and may prove useful in understanding the relationship between
ISCs and colorectal CSCs.
IDENTIFICATION OF INTESTINAL EPITHELIUM STEM CELLS
The intestinal epithelium is one of the most rapidly renewing
tissues in the adult mammalian body, with complete turnover
every 4–5 days (Barker et al., 2008). The small intestine epithe-
lium comprises two histologically distinct structures: the villi
projected toward the gut lumen, and the crypts invaginating into
the mucosa. The villus contains three types of post-mitotic differ-
entiated intestinal cells with the divergent functions of absorption
(enterocytes), mucus secretion (goblet cells), and hormone secre-
tion (endocrine cells). Paneth cells, which secrete lysozyme, reside
at the base of the crypt. The colorectal epithelium lacks villi and
Paneth cells, although the general structure remains similar to that
of the small intestine.
The existence of long-lived ISCs capable of generating all other
types of intestinal cells was ﬁrst proposed by Stevens and Leblond
(1947). Their pulse-chase analysis of 3H thymidine-labeled prolif-
erating cells by autoradiography demonstrated that continuously
proliferating intestinal crypt cells completely replace the villus cells
every 3 days. This ﬁnding later led to the concept that all differenti-
ated intestinal cell types ultimately originate fromundifferentiated
cells residing at the bottom of the crypt, speciﬁcally, the crypt base
columnar cells interspersed between the Paneth cells (Cheng and
Leblond, 1974).
Subsequent work by Potten et al. (1978) found that CBCs
residing at position +4 relative to the crypt bottom retained
the radio-isotopic DNA label, suggesting that these cells were
very slowly dividing or quiescent. Because tissue stem cells were
thought to be relatively dormant to evade DNA damage or telom-
ere shortening during DNA replication, these ﬁndings led later
investigators to assume that +4 position “label-retaining cells”
were the ISCs.
Direct evidence that CBCs were in fact ISCs remained elusive
until 2007, when Barker et al. (2007) using an Lgr5-EGFP-IRES-
creERT2 knock-in transgenic mouse lineage tracing approach,
reported that CBC cells exclusively express the Lgr5 gene, and
these Lgr5+ CBCs generated all types of differentiated intestinal
epithelial cells. Lgr5+ stem cells divide every 24 h, giving rise to
progeny called “transit-amplifying cells” (TA cells) that reside just
above the crypt stem cell zone. TA cells divide vigorously, gener-
ating 16–32 differentiated cells daily. Differentiated epithelial cells
are pushed out along the crypt–villus axis toward the tip of the
villus, before eventually being sloughed off into the gut lumen
4–5 days later (Figure 1).
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FIGURE 1 |The structure of the large intestine crypt. Each crypt comprises crypt base columnar cells (CBC cells) at the bottom, and these CBC cells are
driven toward the lumen as they differentiate.
Similar lineage tracing studies using genes expressed in qui-
escent +4 cells (Bmi1, mTERT, HOPX, and Lrig1) have shown
that these cells can also yield all intestinal epithelial lineages (San-
giorgi and Capecchi, 2008; Montgomery et al., 2011; Takeda et al.,
2011; Powell et al., 2012). This led to the idea that quiescent +4
cells may revert back to robustly dividing Lgr5+ stem cells upon
crypt damage, thus acting as an ISC reservoir (Tian et al., 2011).
Although this explanation may account for the co-existence of
active Lgr5+ cells and quiescent +4 cells with ISC capabilities, it
has since been shown that genes expressed in +4 cells are also
expressed in Lgr5+ cells and differentiated intestinal cells (Munoz
et al., 2012).
Interestingly, secretory progenitor cells that redundantly
express the Notch ligand delta-like1 (Dll1) have been shown to
revert to Lgr5+ stem cells upon intestinal damage (van Es et al.,
2012). More recently, a fraction of Lgr5+ cells were identiﬁed as
the label-retaining cells (LRC) and were shown to be committed
to differentiate into Paneth cells (Buczacki et al., 2013). Buczacki
et al. (2013) using an elegant lineage tracing strategy, demon-
strated that these Lgr5+ LRCs formed clonal crypt structure after
intestinal damage. Although Lgr5+ LRCs andDll1high cells are not
identical in location or Lgr5 expression, these studies indicate plas-
ticity between the secretory progenitors and ISCs and that reserve
pools may exist that can regain stem cell signatures upon crypt
damage.
CELLS OF ORIGIN IN COLORECTAL NEOPLASMS
Terminally differentiated intestinal cells are post-mitotic and have
a lifespan of 4–5 days before being shed into the gut. This short-
lived fate is irreversible and renders it unlikely that they would
accumulate a sufﬁcient number of “driver” mutations for neo-
plastic growth, especially considering that mutagenesis in human
cells is a rare event (Drake et al., 1998). In contrast, ISCs are the
only long-living cells in the intestinal epithelium and are thus
more plausible candidate cells of origin for intestinal tumors
(Figure 2).
Indeed, recent studies have demonstrated that Lgr5+ cells may
also function as stem cells within intestinal adenomas (Barker
et al., 2009). Barker et al. (2009) crossed Lgr5-EGFP-IRES-creERT2
knock-in mice with APCﬂox/ﬂox mice to produce an Lgr5+ stem
FIGURE 2 | A scheme for colorectal cancer stem cell generation from
intestinal stem cells. Intestinal cells are the only long-lived cells in the
human large intestine epithelium and thus can undergo the multiple
mutagenic events required for neoplastic transformation.
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cell-speciﬁc knockout of APC, which resulted in the formation of
macroscopic adenomas. In contrast, upon deletion of APC in TA
or differentiated intestinal cells, these cells only formed micro-
scopic adenomas. These data suggest that Lgr5+ stem cells, but
not their differentiated progeny, are potential cells of origin of
intestinal adenoma.
IDENTIFYING COLORECTAL CANCER STEM CELLS
Cancer stem cells are deﬁned as the cancer cells that drive
tumorigenesis through long-term self-renewal and production of
differentiated, non-tumorigenic progenies. The present gold stan-
dard for deﬁning CSC “stemness” is to show their capacity to
transfer disease into immunodeﬁcient mice at limiting dilutions.
This xenograft assay involves ﬂuorescence-activated cell sorting
(FACS) of single cancer cells that exhibit the putative CSC cell sig-
nature and subsequent quantiﬁcation of their ability to develop
tumors resembling the original tumor. While this assay represents
the only methodology presently available, it is important to con-
sider its limitations when interpreting the resultant data. First, the
CSC markers that have been used to date only enrich, to various
degrees, the CSC fraction within the population; they do not
permit complete discrimination between the CSC and non-CSC
pools. Second, differences between the tumor microenvironment
of the original site and the transplanted recipient may impact
CSC function (Bissell and Labarge, 2005). Growth factors or hor-
mones essential for the tumor growth may be absent, or growth
may be attenuated due to the species barrier between rodents and
humans.
A major focus for CSC research has been the identiﬁcation of
surrogate markers that distinguish CSCs from non-CSCs within
the tumor bulk. With respect to CRC, prominin-1 (CD133) was
initially used as a putative CRC stem cell marker. CD133-positive
cells derived from human CRCs generated tumors histologically
identical to the original tumors in the xenograft assay, whereas
CD133-negative cells showed reduced tumor initiation (O’Brien
et al., 2007). However, this ﬁnding was contested by other stud-
ies demonstrating that CD133-negative cells propagated tumors
as well (Dalerba et al., 2007; Shmelkov et al., 2008). Sorting by
other surface markers, such as CD44 (Dalerba et al., 2007), CD166
(Levin et al., 2010), and ALDH1 (Huang et al., 2009), and by a
combination of such markers was employed to isolate CRC stem
cells in later studies. More speciﬁc markers of ISCs, such as LGR5
or EPHB2, have also been reported to mark the CRC stem cell
population (Merlos-Suarez et al., 2011; Kemper et al., 2012). More
recently, Schepers et al. (2012) demonstrated genetic lineage trac-
ing of Lgr5+ cells within mouse adenomas, indicating that a small
population of cells within the adenoma (5–10%) was responsible
for adenoma self-renewal and production of differentiated Lgr5−
adenoma cells. Comparedwith FACS-based experiments, inwhich
cells are detached from the niche and dissociated into single cells,
genetic lineage tracing experiments might provide more physi-
ological results. Genetic tracing experiments using human CRC
samples are warranted in future studies.
GENETIC ALTERATIONS IN CRC
Colorectal tumors can be stratiﬁed into a number of groups
based on their mutational proﬁle, which suggests several distinct
routes of colorectal neoplastic formation are possible. One well-
establishedpathway is themultistep genetic carcinogenesis initially
proposed by Fearon and Vogelstein (1990). This pathway is
referred to as the adenoma to carcinoma sequence, as CRCs arising
via this pathway originate from tubular adenomas. In particular,
this pathway is triggered byAPC gene inactivation,which results in
ligand-independent Wnt pathway activation, followed by genetic
aberrations in various signaling pathways such as KRAS in RAS–
RAFpathway,SMAD4 in transforming growth factor beta pathway,
PIK3CA in AKT-mTOR pathway, and TP53. These types of CRCs
almost invariably accompany chromosomal aneuploidy or insta-
bility of the genome characterized as chromosomal instability
(CIN).
Shortly after the proposal of a multistep model for CRC
carcinogenesis, subsets of CRCs were shown to carry shorter
repetitive DNA elements or microsatellites than normal tissues
(Ionov et al., 1993). This signature,microsatellite instability (MSI),
marks impairment of the DNA mismatch repair (MMR) sys-
tem and is observed in CRCs from Lynch syndrome or so called
hereditary non-polyposis colon cancer (HNPCC) patients (Pel-
tomaki et al., 1993), as well as in 12–17% of the sporadic CRCs
(Ward et al., 2001; Popat et al., 2005). These sporadic CRCs
with MSI exhibit clearly different molecular signatures from
CIN CRCs: they are near-euploidy or chromosomally stable
and are associated with the BRAF gene mutation (Rajagopalan
et al., 2002). Epigenetic silencing of the MMR genes, mainly
hMLH1, is often observed (Kane et al., 1997). Further investi-
gations have shown that not only hMLH1 but also numerous
other genes comprising CpG dinucleotide-rich promoter regions
are predisposed to epigenetic silencing by promoter methylation
(termed the CpG island methylated phenotype, CIMP; Toy-
ota et al., 1999). Serrated polyps of the colon, predominantly
microvesicular hyperplastic polyps (MVHPs) and sessile serrated
adenoma/polyps (SSA/Ps) were later found to exhibit molecu-
lar features similar to those of MSI CRCs (Yang et al., 2004),
indicating their potential as the precursors of MSI CRCs. This
pathway is referred to as the serrated pathway, arising from
serrated polyps to sporadic CRCs with MSI, successively acquir-
ing the BRAF mutation, CIMP, and MSI along with tumor
development.
Another pathway of colorectal carcinogenesis, the alterna-
tive pathway arising via traditional serrated adenomas (TSAs)
has also been proposed (Shen et al., 2007). This pathway is
associated with KRAS mutation, MGMT (O6-methylguanine-
DNA methyltransferase) methylation and MSI (Ogino et al.,
2007), although the molecular details of this pathway remain
elusive.
Recent large-scale sequencing analyses have identiﬁed recur-
rently mutated genes in CRCs. The initial report by Wood et al.
(2007) demonstrated that approximately 80 genes are mutated in
a typical CRC; however, most of these are neutral, “passenger,”
mutations, and not more than 15 mutations are responsible for
the initiation, progression, or maintenance of the tumor, i.e., are
“driver” mutations. The extensive genetic analysis conducted by
the Cancer Genome Atlas project identiﬁed the frequency and
patterns of altered signaling pathways in sporadic CRCs (Cancer
Genome Atlas, 2012). In this report, the cases were classiﬁed into
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two subtypes, non-hypermutated tumors (with a low frequency
of gene mutations) and hypermutated tumors (with a high muta-
tion frequency), roughly corresponding to CIN CRCs and MSI
CRCs, respectively. Each subtype showed a disparate pattern of
geneticmutations, supporting the idea that they arise fromdiscrete
pathways from which they arise.
EXPANSION OF INTESTINAL STEM CELLS EX VIVO
The long-term culture of non-transformed intestinal cells has pre-
viously been unachievable until we established a method that
enabled the expansion of murine ISCs ex vivo for more than
a year (Sato et al., 2009). This method requires laminin-rich
Matrigel to provide the cells with scaffolds, along with cul-
ture medium containing the growth factors and the hormones
necessary to maintain ISCs: R-spondin 1; EGF; and Noggin.
R-spondin 1 was later identiﬁed as the ligand for Lgr5 and essen-
tial for the effective activation of the Wnt signal (Carmon et al.,
2011). EGF is associated with intestinal proliferation, and Nog-
gin negatively regulates the BMP signal, which induces crypt
differentiation. Under such conditions, ISCs give rise to addi-
tional Lgr5+ cells as well as differentiated intestinal cells and
build three-dimensional cystic crypt–villus structures (organoids),
reminiscent of the in vivo intestinal epithelium. Lgr5+ cells
and Paneth cells reside at the bottom of the crypt component,
whereas the villus component comprises differentiated intesti-
nal cells. These organoids can be grown from a single sorted
Lgr5+ stem cell by addition of the Rho kinase inhibitor, con-
ﬁrming the “stemness” of the Lgr5+ cells. We later demonstrated
that this method could also be applied to human ISCs as well
as human colorectal adenomas and adenocarcinomas with mod-
iﬁcation of the medium content (Sato et al., 2011). The culture
medium for human colorectal stem cells requires Wnt3a, a p38
inhibitor and an ALK 4/5/7 inhibitor in addition to the murine
small intestine culture condition, while the colorectal tumor
organoids can grow in the absence of certain growth factors,
depending on the pathwaymutations they harbor. Most organoids
derived from colorectal neoplasms can grow after the withdrawal
of Wnt3a and R-spondin1, consistent with their APC muta-
tion. Alternatively, KRAS mutation in the organoids renders EGF
dispensable.
APPLICATION OF ORGANOIDS TO CSC STUDY AND
PERSPECTIVES
A forward genetic approach is essential for functional analysis
of the candidate genes involved in CRC stem cell development
from ISCs. Genetically engineered mice such as Lgr5-EGFP-IRES-
creERT2/APCﬂox/ﬂox mice allow the in situ observation of tumor
generation from normal intestinal epithelium and the kinetics of
the stem cells within the tumor (Barker et al., 2009). However,
the establishment of genetically engineered strains requires sub-
stantial time, effort and cost, especially when handling multiple
genes. Clearly, similar approaches in humans are not possible,
with the very rare exceptions of patients with certain inherited
disorders.
Organoids are amenable to gene overexpression or knockdown
by viral infection (Koo et al., 2012), which provide a unique tool
to study the phenotypes resulting from the manipulation of gene
expression in human ISCs. Furthermore, Schwank et al. (2013)
recently demonstrated the application of the CRISPR/Cas9 system
for genome targeting in organoids. In this report, the cystic ﬁbrosis
transmembrane conductor receptor (CFTR) gene of the intestinal
organoids, derived from cystic ﬁbrosis patients, was corrected by
homologous recombination via the CRISPR/Cas9 system. A sim-
ilar methodology can be employed in the context of oncogenes
or tumor suppressor genes as well. In summary, the ability to
use organoid culture to model the genetic alterations associated
with CRC carcinogenesis provides a promising method by which
the genetic events involved in CRC stem cell generation can be
functionally studied.
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